Niagen Bioscience (NASDAQ:NAGE - Get Free Report) had its target price increased by equities researchers at Roth Capital from $10.00 to $23.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Roth Capital's price objective suggests a potential upside of 78.71% from the stock's previous close.
Separately, Canaccord Genuity Group initiated coverage on shares of Niagen Bioscience in a report on Tuesday, May 27th. They set a "buy" rating and a $13.00 price objective for the company.
Check Out Our Latest Report on Niagen Bioscience
Niagen Bioscience Stock Up 11.8%
Shares of NAGE stock traded up $1.36 during trading hours on Friday, reaching $12.87. The company had a trading volume of 659,987 shares, compared to its average volume of 844,907. Niagen Bioscience has a twelve month low of $2.31 and a twelve month high of $12.87. The company's fifty day simple moving average is $8.45. The stock has a market capitalization of $1.01 billion, a P/E ratio of 75.71 and a beta of 1.94.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
